Document is current
Any future updates will be listed below
-
Authors
Yeu, Elizabeth
Paauw, James D.
Vollmer, Patrick
Berdy, Gregg J.
Whitson, William E.
Meyer, John
Simmons, Blake
Peterson, Jared D.
Periman, Laura M.
Boehmer, Blair E.
Bloomenstein, Marc R.
Whitley, Walter O.
Koetting, Cecelia
Dhamdhere, Kavita
Neervannan, Sesha
Ciolino, Joseph B.
-
Funding
Funding for this research was provided by:
Tarsus Pharmaceuticals
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 11 December 2024
First Online: 28 January 2025
Declarations
:
: Elizabeth Yeu had received consulting fees from, served on the board of directors of, and was an equity stakeholder in Tarsus Pharmaceuticals during the conduct of Saturn-1 and Saturn-2 trials and the planning and execution of this pooled analysis, before becoming an employee of Tarsus Pharmaceuticals. William E. Whitson is an equity stakeholder in Tarsus Pharmaceuticals. Marc R. Bloomenstein, Joseph B. Ciolino, Cecelia Koetting, Laura M. Periman, Patrick Vollmer, and Walter O. Whitley have received consulting fees from Tarsus Pharmaceuticals. Elizabeth Yeu, Kavita Dhamdhere and Sesha Neervannan are employees of Tarsus Pharmaceuticals. Joseph B. Ciolino, Jared D. Peterson, James D. Paauw, and Patrick Vollmer received research fees from Tarsus Pharmaceuticals or Ora Clinical Research. Blake Simmons, Gregg J. Berdy, John Meyer, and Blair E. Boehmer report no conflicts of interest related to this manuscript.
: The two studies analyzed in this post hoc analysis adhered to the tenets of the Declaration of Helsinki and were approved by the Institutional Review Board (IRB). All enrolled patients provided written informed consent using the IRB-approved informed consent forms.
